NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Biotechnology · CAD

Medicenna Therapeutics Corp. (MDNA.TO) Stock Analysis

Medicenna Therapeutics Corp. (MDNA.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.

MDNA.TO

CA$0.47

CA$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MDNA.TO with… →

MDNA.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$0.48
Previous Close
CA$0.47
Day's Range
0.47–0.48
52-Week Range
0.34–1.97
Volume
14.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.96
Valuation
Market Cap
CA$43.38M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.22
Financials (FY)
Revenue (FY)
CA$0.00
Net Income (FY)
−CA$18.41M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
92.30M
1-Year Return
−55.66%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
56.20K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MDNA.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−48.91%
2025−44.24%
2024+292.86%
2023−34.38%
2022−69.52%
2021−64.71%
2020+75.00%
2019+385.71%
2018−65.00%
2017 (partial year)−25.93%

As of September 4, 2026.

MDNA.TO Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025CA$0.00−CA$18.41M—
2024CA$0.00−CA$11.81M—
2023CA$0.00−CA$25.47M—
2022CA$0.00−CA$10.05M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$0.00—−CA$22.42M−CA$18.41M—
2024CA$0.00—−CA$20.41M−CA$11.81M—
2023CA$0.00—−CA$18.67M−CA$25.47M—
2022CA$0.00—−CA$16.30M−CA$10.05M—

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

MDNA.TO Valuation vs Biotechnology Median

Median of 656 stocks
MetricMDNA.TOBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Medicenna Therapeutics Corp. (MDNA.TO) carries a market capitalisation of CA$43.38M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 15.

MDNA.TO last closed at CA$0.47 on September 4, 2026. The close was unchanged from the previous session. The 52-week range on file runs from CA$0.34 to CA$1.97. The latest close sits 40.3% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to CA$0.00. The same year closed with a net loss of CA$18.41M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.22.

Across the 4 fiscal years on file, revenue moves from CA$0.00 in 2022 to CA$0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.96. Annualized volatility over the trailing 9 years is 93.61%. The trailing one-year price return is −55.66%. Measured over 5 years, that is −30.98% a year compounded.

Growth & Income

The record shows no dividend for MDNA.TO.

The strongest complete calendar year on file is 2019 at +385.71%; the weakest is 2022 at −69.52%. Of the 8 complete calendar years on file, 3 finished higher. So far in 2026 the price is −48.91%.

Peer Comparison

Medicenna Therapeutics Corp. (MDNA.TO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Medicenna Therapeutics Corp. MDNA.TO CA$43.38M —
Vertex Pharmaceuticals Incorporated VRTX CA$138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN CA$85.22B 20.5
argenx SE ARGX CA$64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Medicenna Therapeutics Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Visit website →